13/02/2014
MELANOMA CENTER
The Hadassah Melanoma and Cancer Immunotherapy Center (HMCIC) has an active and diverse program for melanoma treatment. In addition to standard therapies, the Center offers several unique treatment options aimed at strengthening the patient's immune response against his tumor. This approach is termed Immunotherapy.
The Hadassah Melanoma Center offers two vaccine immunotherapies, aimed at treatment of stage III and IV patients who have undergone surgery to remove one or more metastases. Patients who show no evidence of additional tumor foci after surgery are eligible for one of the following vaccines:
• The Autologous Vaccine, prepared from the patient's own tumor cells, obtained from a biopsy during surgery.
• The Allogeneic Vaccine which is prepared from a mix of several tumor cell lines maintained at the center. For each patient, lines with a degree of similarity with the patient's own cells are chosen.
By administering the vaccine, we try to strengthen the immune response against the tumor, in order to prevent or delay metastatic recurrence and prolong survival. Our team at Hadassah has had many years of experience and numerous successes with the administration of these vaccines.
The Hadassah Melanoma and Cancer Immunotherapy Center often takes part in international multicenter clinical trials sponsored by pharmaceutical companies developing new drugs for the treatment of metastatic melanoma. Hadassah's Melanoma and Cancer Immunotherapy Center has also several active research programs aimed at enhancing the efficacy of melanoma immunotherapy.
For more information please contact:
ofekmed@gmail.com
For medical tourism inquiries, please contact Ziv +972-36818080 or mail ofekmed@gmail.com